The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | PHILEMON trial: ibrutinib, lenalidomide and rituximab in R/R MCL
Mats Jerkeman, MD, PhD, Skane University Hospital, Lund, Sweden, discusses the final results of the PHILEMON Phase II trial (NCT02460276) evaluating ibrutinib, lenalidomide and rituximab in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL). The results show a median progression-free survival of 19 months, which is comparable to ibrutinib alone. The regimen has good efficacy in patients with TP53 mutation and therefore could be a treatment option for high-risk MCL. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Research support: Janssen, Celgene, Abbvie, Roche, Gilead
Honoraria: Celgene, Gilead, Roche, Incyte
